Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.

Pharmacogenomics - 1 Jun 2017

Damkier Per

Abstract excerpt

Letter in resonse to: Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 17(18), 1967-1969 (2016).

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Meta-Analysis as Topic

Share to Pharmacogenetics

Share to Tamoxifen

Source

Identifiers

PMID: 28592184
DOI: 10.2217/pgs-2017-0190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.PMID 28592184Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

The ethics of CYP2D6 testing for patients considering tamoxifen.Semantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapySemantic proximity Read ↗

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

CYP2D6 genotyping and the pharmacogenetics of tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.